Neuroprotective actions of glucagon-like peptide-1 (GLP-1) analogues in alzheimers and parkinsons diseases
Increasing fiber, fluids, and physical activity usually helps resolve this issue
However, several challenges hinder its large-scale application and industrial adoption
To assess the association of semaglutide with incident AUD, the study population included 598,803 patients with T2DM who had active medical encounters for T2DM during 12/20175/2021, were for the first time prescribed semaglutide or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Could GLP-1 drugs curb addiction